This page discusses chronic myelogenous leukemia (CML), a blood cancer caused by the BCR-ABL chimeric protein leading to unchecked myeloid cell growth. The targeted therapy Gleevec™ (imatinib) inhibit...This page discusses chronic myelogenous leukemia (CML), a blood cancer caused by the BCR-ABL chimeric protein leading to unchecked myeloid cell growth. The targeted therapy Gleevec™ (imatinib) inhibits this protein's kinase activity, effectively managing the disease but not curing it. Treatment challenges arise from patient variability and potential drug resistance, complicating effective management of CML.